The issue is risk taking. As the Pelosi bill cuts returns and raises the cost of capital, risk taking in life sciences will decline. We’ll still get new drugs, but we’ll lose the big bets on the highest risk science like gene editing, regenerative medicine
There's an entire industry Washington is leaving out of the debate over high drug prices, and they're the ones we perhaps should be paying the most attention to. I tell their story here. (Also H/T to for this great GIF.)
Missing from the drug pricing debate is an important perspective: the voice of small #biotechs who are uniquely worried about short-sighted policies being considered to #LowerDrugCosts. Learn why #HR3Impact rpt in
It’s tiny biotechs — not big drug makers — that fear "nuclear winter" from Pelosi’s drug pricing bill.
Missing from the drug pricing debate is an important perspective: the voice of small #biotechs who are uniquely worried about short-sighted policies being considered to #LowerDrugCosts. Learn why+see coverage of #HR3Impact rpt in
Washington hasn’t spent much time considering how small biotech companies will fare under Pelosi’s drug pricing bill — but CEOs said they predict a “devastating effect” on investment.
With current pricing mechanisms we have is it even possible to improve affordability without upsetting the equilibrium elsewhere? We need new ideas about how to incentivise innovation Tiny biotechs fear ‘nuclear winter’ from Pelosi drug pricing bill
They should be worried because the bill is designed primarily to extract maximum donations to DC politicians as far as I can tell, classic mercantilism
I read this today & if bill goes through it prob impacts Recursion, Atomwise, Tmunity, Freenome, Unlearn & future companies like them. If agree, consider speaking out
Tiny biotechs fear ‘nuclear winter’ from Pelosi drug pricing bill
An entire article about impact of lower drug prices on small biotech with only one use of the word ‘innovation.’ 👍 What I wish had asked is what amount of price reduction would be okay to small biotech. Part D inflation cap?
Also, this line is something. Kudos to VC and biotech for enduring. ‘“Raising venture capital funding is like a colonoscopy, “although it’s much longer than a colonoscopy,” Potential investors probe every orifice of a company...’